NCT06116903

Clinical Relevance of Detecting Molecular Abnormalities in Glial Tumor Exosomes

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: University Hospital, Limoges · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this pilot study is that exosomes constitute a more interesting support for analyzes allowing a broader screening of molecular alterations to be carried out with more reliable, more sensitive and more efficient results than the reference Foundation One Liquid CDx test.

Detailed description

Gliomas are the most common primary brain tumors in adults. The heterogeneity of tumors, the lack of reliable criteria for identifying different subtypes make their histopathological diagnosis and their management complex. The molecular profiling from circulating exosomes is one of the most promising approaches to better characterize gliomas. We will demonstrate the superiority of detection by NGS of molecular abnormalities present in exosomes from glioblastomas, compared to detection by the Foundation One Liquid CDx test on ctDNA.

Conditions

• Glioma

Interventions

Type	Name	Description
GENETIC	Blood sampling	Blood sampling for testing of the detection of molecular abnormalities in exosomes of glial tumors

Timeline

• Start date: 2024-04-11
• Primary completion: 2025-05-15
• Completion: 2025-12-15
• First posted: 2023-11-03
• Last updated: 2024-12-13

Locations

1 site across 1 country: France